Opdivo gains European approval for Hodgkin lymphoma
Latest approval for Opdivo good news, but won’t make up for lung cancer setback
Opdivo
NICE and NHS England unveil ‘fast-track’ and affordability shake-up
NHS England, NICE, Opdivo
0 Comment
NHS England will be able to control cost impact of NICE decisions more directly.
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
BMS, breakthrough, cancer, docetaxel, ESMO, kantar, Keytruda, Merck, Opdivo, Roche, Tecentriq, trial
0 Comment
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Cancer Market Commentary: Keytruda’s triumph not the last word in NSCLC
2016, cancer, development, ESMO, Keytruda, Opdivo, pharma, treatment
0 Comment
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
BMS and Nektar to pair Opdivo with natural killer cell drug
BMS, immunotherapy, Nektar Therapeutics, NSCLC, Opdivo, PD-1
0 Comment
BMS and Nektar’s combination latest in frenzied immunotherapy field
Merck makes its move: Keytruda filed for first line lung cancer
BMS, immunotherapy, Keytruda, Merck, NSCLC, Opdivo
0 Comment
Merck steals a march on rival BMS.
Bavarian and BMS press on with Opdivo and cancer vaccine combo
BMS, immunotherapy, Oncology, Opdivo
0 Comment
BMS hopes combinations will maintain Opdivo lead after setback
Promise for combination approach to cancer
4-1BB, cancer, immuno-oncology, immunotherapy, Keytruda, Oncology, Opdivo, PD-1, R&D, T-cell
0 Comment
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Imbruvica, Opdivo and Praluent gain approvals for Scotland’s NHS
Cosentyx, Imbruvica, melanoma, Opdivo, Quinsair, Scottish Medicines Consortium
0 Comment
Sanofi steals a march on rivals Amgen